Osteal Therapeutics Closes An Oversubscribed $30 Million Series B Financing To Advance Platform Therapy For Treatment Of Musculoskeletal Infection
Amount Raised
$30 Million
Round Type
Series B
DallasOtherHealthcareHealth CareDescription
Osteal Therapeutics, Inc. (“Osteal”), a clinical-stage biopharmaceutical company developing a new category of combination therapies for musculoskeletal infections, announced today the completion of an oversubscribed $30 million Series B equity financing. The proceeds will enable Osteal to continue development of its integrated technologies, advance the clinical development of its lead candidate, VT-X7 for treatment of periprosthetic joint infection and fund new research programs.
Who to call at Osteal Therapeutics, and when
A new round usually means Osteal Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Osteal Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Osteal Therapeutics, from your own LinkedIn network
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Osteal Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansOsteal Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.